News

Catch up on this week's highlights in retina.

Franklin shares how methotrexate significantly reduces reoperation rates in diabetic patients with retinal detachments, enhancing postoperative outcomes and vision.

4D Molecular Therapeutics showcases promising SPECTRA trial results for 4D-150, highlighting its potential to revolutionize diabetic macular edema treatment.

The DAVIO-2 study reveals EYP-1901's potential as a 6-month treatment for neovascular AMD, matching aflibercept's vision outcomes with fewer doses.

New research identifies key factors influencing visual recovery in Leber hereditary optic neuropathy patients treated with gene therapy, enhancing treatment strategies.

Matthew Starr, MD, discusses techniques for correcting astigmatism in patients lacking capsular support, enhancing visual outcomes surgery.

Lai spoke with Modern Retina about the study of PER-001, a novel therapeutic targeting the endothelin-1 receptor.

Avant Technologies and Ainnova Tech refine clinical trial protocol for Vision AI platform, aiming for FDA 510(k) approval to enhance diabetic retinopathy detection.

Clearside Biomedical secures Health Canada approval for Xipere, while exploring strategic options to enhance its suprachoroidal delivery platform and pipeline.

Justis Ehlers, MD, FASRS, presented "PER-001, a Long-acting Endothelin Antagonist Intravitreal Implant, Improved Structure and Visual Function in Patients With Diabetic Retinopathy," during the 2025 ASRS meeting held in Long Beach, California.

Catch up on this week's highlights in retina.

Christina Weng, MD, MBA, FASRS, explores the viability of postoperative day 0 exams as a substitute for day 1 after vitreoretinal surgery, revealing promising findings.

Researchers reveal that retinal microvasculature analysis via OCTA may enhance noninvasive cardiovascular risk assessment, potentially improving coronary artery stenosis detection.

Andrew G. Lee, MD, shares essential insights on neuro-ophthalmology for retina specialists, emphasizing diagnosis techniques and collaboration with neuro-ops.

Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025.

Topcon Healthcare enhances its connected care model by acquiring IRIS, integrating AI for improved diabetic eye disease screening and patient coordination.

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.

Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025.

Notably, Alcon will be providing a demo of the UNIPEXY Gas Delivery System.

EYLUXV, a new biosimilar for treating serious eye conditions, gains positive EMA recommendation, promising improved patient access and outcomes.

In preparation for the American Society of Retina Specialist (ASRS) annual meeting being held in Long Beach, California, Modern Retina spoke with Gaurav Shah MD, FASRS, Program Chair of the 2025 event.

Re-Vana Therapeutics and Boehringer Ingelheim forge a $1 billion partnership to develop innovative extended-release therapies for eye diseases, enhancing patient care.